Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar

被引：3
|
作者：
Pagnini, Cristiano [1 ]
Di Paolo, Maria Carla [1 ]
De Angelis, Giulia [1 ]
Torcolacci, Federica [1 ]
Milano, Michele [1 ]
Trinca, Daniela [1 ]
Porciello, Roberto [2 ]
Graziani, Maria Giovanna [1 ]
机构：
[1] S Giovanni Addolorata Hosp, Dept Gastroenterol & Digest Endoscopy, Rome, Italy
[2] S Giovanni Addolorata Hosp, Dept Dermatol, Rome, Italy
来源：
INFLAMMATORY BOWEL DISEASES | 2020年 / 26卷 / 08期
关键词：
infliximab biosimilar; CT-P13; BS2; Crohn's disease; psoriasis; IMMUNOGENICITY;
D O I：
10.1093/ibd/izaa128
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E83 / E84
页数：2
相关论文
共 50 条
  • [41] Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study
    Petitdidier, Nicolas
    Tannoury, Jenny
    de'Angelis, Nicola
    Gagniere, Charlotte
    Hulin, Anne
    Rotkopf, Hugo
    Mesli, Farida
    Brunetti, Francesco
    Sobhani, Iradj
    Amiot, Aurelien
    DIGESTIVE AND LIVER DISEASE, 2019, 51 (12) : 1652 - 1660
  • [42] Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar(CT-P13) in patients with inflammatory bowel disease
    María Fernanda Guerra Veloz
    Federico Argüelles-Arias
    Luisa Castro Laria
    Belén Maldonado Pérez
    Antonio Benítez Roldan
    Raúl Perea Amarillo
    Vicente Merino Bohórquez
    Miguel Angel Calleja
    ángel Caunedo álvarez
    ángel Vilches Arenas
    World Journal of Gastroenterology, 2018, (46) : 5288 - 5296
  • [43] Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
    Guerra Veloz, Maria Fernanda
    Arguelles-Arias, Federico
    Castro Laria, Luisa
    Maldonado Perez, Belen
    Benitez Roldan, Antonio
    Perea Amarillo, Raul
    Merino Bohorquez, Vicente
    Angel Calleja, Miguel
    Caunedo Alvarez, Angel
    Vilches Arenas, Angel
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (46) : 5288 - 5296
  • [44] BIOSIMILAR INFLIXIMAB (CT-P13) IS NOT INFERIOR TO ORIGINATOR INFLIXIMAB: EXPLORATIVE IBD SUBGROUP-ANALYSES IN CROHN'S DISEASE AND ULCERATIVE COLITIS FROM THE NOR-SWITCH TRIAL
    Joergensen, Kristin K.
    Olsen, Inge C.
    Goll, Guro L.
    Lorentzen, Merete
    Bolstad, Nils
    Berset, Ingrid P.
    Haavardsholm, Espen A.
    Lundin, Knut E.
    Mork, Cato
    Kvien, Tore K.
    Jahnsen, Jorgen
    GASTROENTEROLOGY, 2017, 152 (05) : S65 - S66
  • [45] Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial
    Jorgensen, K. K.
    Olsen, I. C.
    Goll, G. L.
    Lorentzen, M.
    Bolstad, N.
    Berset, I. P.
    Haavardsholm, E. A.
    Lundin, K. E.
    Mork, C.
    Kvien, T. K.
    Jahnsen, J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S62 - S63
  • [46] Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center
    Bronswijk, Michiel
    Moens, Annick
    Lenfant, Matthias
    Tops, Sophie
    Compernolle, Griet
    Van Assche, Gert
    Vermeire, Severine
    Gils, Ann
    Ferrante, Marc
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (04) : 628 - 634
  • [47] Infliximab-Biosimilar CT-P13 Phase-III-Study confirms Non-Inferiority for Reference in Patients with Crohn's Disease
    不详
    VISCERAL MEDICINE, 2019, 35 (03) : 198 - 198
  • [48] Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's disease and ulcerative colitis-54 week data
    Molnar, T.
    Farkas, K.
    Rutka, M.
    Ferenci, T.
    Nagy, F.
    Balint, A.
    Bor, R.
    Milassin, A.
    Fabian, A.
    Vegh, Z.
    Kurti, Z.
    Lakatos, P. L.
    Szepes, Z.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S425 - S426
  • [49] DISEASE WORSENING AND SAFETY IN PATIENTS SWITCHING FROM ORIGINATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN THE NOR-SWITCH STUDY: EXPLORATIVE ANALYSIS OF RA PATIENTS
    Goll, G. L.
    Olsen, I. C.
    Bolstad, N.
    Jorgensen, K. K.
    Lorentzen, M.
    Mork, C.
    Jahnsen, J.
    Haavardsholm, E. A.
    Kvien, T. K.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 549 - 550
  • [50] Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease
    Lisa J. T. Smits
    Anna Grelack
    Lauranne A. A. P. Derikx
    Dirk J. de Jong
    Aura A. J. van Esch
    Ronald S. Boshuizen
    Joost P. H. Drenth
    Frank Hoentjen
    Digestive Diseases and Sciences, 2017, 62 : 3117 - 3122
12345